Get the Stockscreener App
339.30
0.56%
1.88
After Hours:
338.05
-1.25
-0.37%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $339.30, with a volume of 1.47M.
It is up +0.56% in the last 24 hours and down -1.91% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$337.42
Open:
$340.26
24h Volume:
1.47M
Relative Volume:
0.56
Market Cap:
$183.22B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.60
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+3.98%
1M Performance:
-1.91%
6M Performance:
+0.52%
1Y Performance:
+24.79%
1-Day Range:
$338.40
$343.80
1-Week Range:
$320.96
$343.80
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
339.30 | 182.21B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. stock (US0311621009): obesity data, Horizon deal and pipeline put focus back on the biote - AD HOC NEWS
Keudell Morrison Wealth Management Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
Global Retirement Partners LLC Purchases 5,691 Shares of Amgen Inc. $AMGN - MarketBeat
A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate - Yahoo Finance
Amgen Inc. Stock 12‑Month Price Target Cut to $352.32, Implies 4% Upside - TradingView
Amgen stock (US0311621009): Q1 revenue tops estimates, CFO change keeps debt in focus - AD HOC NEWS
Amgen Shareholders Reaffirm Board, Pay and Auditors - The Globe and Mail
Amgen’s ‘boomerang’ CFO reaps $12.5M in cash, retention bonuses - CFO Dive
Amgen CFO Change Puts Focus On Debt, Growth And Capital Discipline - simplywall.st
Amgen Drug Gets New Warnings in Japan After Patient Deaths - WSJ
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
The Escalator: Amgen, CG Life, Cosette Pharmaceuticals and more - Medical Marketing and Media
IFP Advisors Inc Has $3.92 Million Stake in Amgen Inc. $AMGN - MarketBeat
Liquidity Mapping Around (AMGN) Price Events - Stock Traders Daily
Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth - Insider Monkey
ABN Amro Investment Solutions Acquires 13,431 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen's CFO resigns – a successor has been named - medwatch.com
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Amgen Inc. 8-K Filing May 2026: Executive Compensation Approval and Shareholder Voting Results - Minichart
Declaration of Voting Results by Amgen Inc - marketscreener.com
As Griffith retires, Dittrich returns to Amgen, takes CFO role - biocentury.com
The Story of Maridebart Cafraglutide (MariTide) - Amgen
Amgen’s Approach to AI-Enabled Clinical Development - Amgen
Amgen : Approach to AI-Enabled Clinical Development - marketscreener.com
Amgen Advances Xaluritamig Trial in Hard-to-Treat Prostate Cancer - TipRanks
Amgen Inc. stock (US0311621009): Weight-loss drug data and guidance update keep investors on alert - AD HOC NEWS
Amgen, bidding adieu to CFO, lures Galderma exec with hefty $12.4M bonus - Fierce Pharma
Argus Adjusts Price Target on Amgen to $375 From $400, Maintains Buy Rating - marketscreener.com
PNC Financial Services Group Inc. Has $343.34 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen announces CFO Peter Griffith retiring - The Pharma Letter
Cullen Frost Bankers Inc. Cuts Stake in Amgen Inc. $AMGN - MarketBeat
Fairtree Asset Management Pty Ltd Acquires New Stake in Amgen Inc. $AMGN - MarketBeat
Harvest Portfolios Group Inc. Lowers Stock Position in Amgen Inc. $AMGN - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Banque Cantonale Vaudoise - MarketBeat
Atle Fund Management AB Has $7.17 Million Stake in Amgen Inc. $AMGN - MarketBeat
AMGN News | AMGEN INC (NASDAQ:AMGN) - ChartMill
Standing Bone Strong: Introducing a New Awareness Symbol for Osteoporosis - Amgen
Amgen Inc. (AMGN) Announces CFO Transition with Retirement of Pe - GuruFocus
Amgen Earnings Call Highlights Growth Amid Headwinds - TipRanks
Amgen stock (US0311621009): CFO succession and analyst reaction keep focus on biotech heavyweight - AD HOC NEWS
Amgen says CFO Peter Griffith to retire, names Dittrich as successor - WTAQ
Amgen stock (US0311621009): FDA data and pipeline updates in focus - AD HOC NEWS
Amgen (AMGN) Announces CFO Transition with Peter Griffith's Reti - GuruFocus
Amgen (AMGN) Announces CFO Transition as Peter Griffith Retires - GuruFocus
Amgen announces CFO transition - MSN
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen names Thomas Dittrich as new CFO effective September By Investing.com - Investing.com Canada
Amgen Inc. Announces Chief Financial Officer Changes, Effective September 1, 2026 - marketscreener.com
Is It Time To Reassess Amgen (AMGN) After Its Strong Multi Year Share Price Run - simplywall.st
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):